All In MedTech

FDA Clearance Tracker · P160043

RESOLUTE ONYX ZOTAROLIMUS-ELUTING CORONARY STENT SYSTEM

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Apr 28, 2017 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Apr 28, 2017

Approved

Time to decision

213 days

Received Sep 27, 2016. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P160043
Device name
RESOLUTE ONYX ZOTAROLIMUS-ELUTING CORONARY STENT SYSTEM
Applicant location
Santa Rosa, CA
Received
Sep 27, 2016
Decided
Apr 28, 2017
Decision
Approved
Supplements
88 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code NIQ

FDA's approval statement

As written in FDA's record.

Approval for the Resolute Onyx Zotarolimus-Eluting Coronary Stent System. This device is indicated for improving coronary luminal diameters in patients, including those with diabetes mellitus, with symptomatic ischemic heart disease due to de novo lesions of length less than or equal to 35 mm in native coronary arteries with reference vessel diameters of 2.25 mm to 5.0 mm.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code NIQ. The earliest in FDA's data is P020026, decided Apr 24, 2003.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Medtronic Vascular

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.